Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03579472
Title M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

triple-receptor negative breast cancer

Therapies

Eribulin + M7824

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.